|
Risk
| | |
|
BRCA1 DNAm signature (1,829 CpGs)
|
Breast
|
Whole blood DNA [65]
|
|
140 variable CpGs
|
Cervical
|
Normal uterine cervix cells [58]
|
|
Diagnosis
| | |
|
GSTP1
|
Prostate
|
Serum, urine, ejaculate [70]
|
|
APC, EDNRB, GSTP1
|
Prostate
|
Urine [71]
|
|
CDKN2A, ARF, MGMT, GSTP1
|
Prostate
|
Urine [72]
|
|
GSTP1, APC, PTGS2
|
Prostate
|
Paraffin-embedded tissues [110]
|
|
SETP9
|
Colorectal
|
Blood plasma [77]
|
|
APC, MGMT, RASSF2A, WIF1
|
Colorectal
|
Blood plasma [78]
|
|
SHOX2
|
NSCLC
|
Bronchial fluid aspirates/ blood plasma [76]
|
|
CDKN2A, MGMT
|
NSCLC
|
Sputum [74]
|
|
CCND2, RASSF1A, APC, HIN1
|
Breast
|
Fine needle aspiration biopsy [111]
|
|
ZNF154, HOXA9, POU4F2, EOMES
|
Bladder
|
Urine [112]
|
|
Prognosis
| | |
|
20-gene signature
|
ALL
|
Leukemic cells from bone marrow and peripheral blood [88]
|
|
15-gene classifier
|
AML
| |
|
RASSF1A, APC
|
Breast
|
Serum [82]
|
|
ZAP70
|
CLL
|
CD19 sorted mononuclear cells [80]
|
|
CDKN2A
|
CCR
|
Blood plasma [81]
|
|
DAPK1
|
Head and neck
|
Tumor samples [84]
|
|
DAPK1
|
NSCLC
|
Tumor samples [83]
|
|
CDKN2A, RASSF1A, CDH13, APC
|
NSCLC
|
Primary tumors and lymph nodes [85]
|
|
HIST1H4F, PCDHGB6, NPBWR1, ALX1, HOX9
|
NSCLC
|
Tumor samples [89]
|
|
ALDH1A, OSR2, GATA4, GRIA4, IRX4
|
OPSCC
|
Tumor samples [59]
|
|
GSTP1, APC, PTGS2
|
Prostate
|
Tumor samples [110]
|
|
Response to therapy
| | |
|
BRCA1
|
Breast
|
Tumor samples [92],[93]
|
|
BCL2
|
Breast
|
Tumor samples [113]
|
|
PITX2
|
Breast
|
Tumor samples [114]
|
|
TFAP2E
|
Colon
|
Tumor samples [115]
|
|
MGMT
|
Glioma
|
Tumor samples [90],[91]
|
|
APAF1
|
Melanoma
|
Tumor samples/cell lines [116]
|
|
IGFBP3
|
NSCLC
|
Tumor samples/cell lines [117]
|
|
BRCA1
|
Ovary
|
Tumor samples [94]
|
